Alabama

Psychedelic trials in Alabama

25 registered trials has a study site in Alabama, and 5 are recruiting now.

Trials with a site here

Recruiting

Facilities

Open now

Recruiting in this state

Trial	Status	Phase	Substance	Sites
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderNCT06793397 · Cybin IRL Limited	Recruiting	Phase 3	psilocybin	68
Psilocybin Intervention for Veterans Overcoming Treatment-Resistant DepressionNCT07226232 · VA Office of Research and Development	Recruiting	Phase 3	psilocybin	5
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive DisorderNCT07227454 · Janssen Research & Development, LLC	Recruiting	Phase 3	ketamine	35
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use DisorderNCT05452772 · Johns Hopkins University	Recruiting	Phase 2	psilocybin	3
Psilocybin-facilitated Treatment for Chronic PainNCT05068791 · University of Alabama at Birmingham	Recruiting	Early Phase 1	psilocybin	1

Facilities

Where the research happens in Alabama

Facility	City	Trials
University of Alabama at Birmingham	Birmingham	5
Tuscaloosa VA Medical Center, Tuscaloosa, AL	Tuscaloosa	2
UAB Department of Psychiatry and Behavioral Neurobiology	Birmingham	2
UAB Psychiatry and Behavioral Neurology	Birmingham	1
Birmingham VA Medical Center, Birmingham, AL	Birmingham	1
UAB Beacon Tower	Birmingham	1
UAB Huntsville Regional Medical Campus	Huntsville	1
University of Alabama Clinical Research Unit	Birmingham	1
UAB Outpatient Clinical Research Unit	Birmingham	1
Novartis Investigative Site	Birmingham	1
Research Site, Birmingham	Birmingham	1
University of Alabama Hospital	Birmingham	1
UAB Medicine \| Heersink School of Medicine	Birmingham	1
University of Alabama Birmingham	Birmingham	1

Stay told

When a trial opens in Alabama

All trials

Every trial with a Alabama site

Trial	Status	Phase	Substance	Sites
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderNCT06793397 · Cybin IRL Limited	Recruiting	Phase 3	psilocybin	68
Psilocybin Intervention for Veterans Overcoming Treatment-Resistant DepressionNCT07226232 · VA Office of Research and Development	Recruiting	Phase 3	psilocybin	5
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive DisorderNCT07227454 · Janssen Research & Development, LLC	Recruiting	Phase 3	ketamine	35
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use DisorderNCT05452772 · Johns Hopkins University	Recruiting	Phase 2	psilocybin	3
Psilocybin-facilitated Treatment for Chronic PainNCT05068791 · University of Alabama at Birmingham	Recruiting	Early Phase 1	psilocybin	1
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant DepressionNCT04599855 · Janssen Research & Development, LLC	Completed	Phase 4	ketamine	54
VA Aripiprazole vs Esketamine for Treatment Resistant DepressionNCT05554627 · VA Office of Research and Development	Withdrawn	Phase 4	ketamine	26
Psilocybin for Major Depressive Disorder (MDD)NCT06308653 · Usona Institute	Active, not recruiting	Phase 3	psilocybin	29
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionNCT02417064 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	90
A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionNCT02418585 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	48
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant DepressionNCT02493868 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	155
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant DepressionNCT02782104 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	173
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideNCT03039192 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	56
Psilocybin for Methamphetamine Use DisorderNCT07774702 · Peter Hendricks	Not yet recruiting	Phase 2	psilocybin	1
Psilocybin-facilitated Treatment for Cocaine UseNCT02037126 · University of Alabama at Birmingham	Completed	Phase 2	psilocybin	1
A Study of Ketamine in Patients With Treatment-resistant DepressionNCT01627782 · Janssen Research & Development, LLC	Completed	Phase 2	ketamine	13
A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant DepressionNCT01998958 · Janssen Research & Development, LLC	Completed	Phase 2	ketamine	25
A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for SuicideNCT02133001 · Janssen Research & Development, LLC	Completed	Phase 2	ketamine	14
miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment OutcomeNCT02418195 · University of Alabama at Birmingham	Completed	Phase 2	ketamine	1
Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant DepressionNCT03756129 · Novartis Pharmaceuticals	Completed	Phase 2	ketamine	12
Sequential Therapy for the Treatment of Severe Bipolar Depression.NCT02974010 · NeuroRx, Inc.	Completed	Phase 2	ketamine	4
Exploratory Study of Low Dose PsilocybinNCT05227742 · University of Alabama at Birmingham	Withdrawn	Early Phase 1	psilocybin	1
Effect of Ketamine and Etomidate During RSI on Long Term OutcomesNCT06179485 · Vanderbilt University Medical Center	Enrolling by invitation	N/A	ketamine	6
Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse PreventionNCT04760652 · Yale University	Completed	Not applicable	ketamine	3
Treatment of Suicidal Ideation With Intravenous Ketamine InfusionNCT01887990 · University of Alabama at Birmingham	Completed	Not applicable	ketamine	1

Site locations from ClinicalTrials.gov API v2, data build 2026-08-25.

Elsewhere